Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc.

CATXNYSE / NASDAQHealthcareSmall cap

$0.75-$0.03 (-3.8%)

Last close · Data as of Nov 20, 2026

Market cap
$370.7M
P/E
-3.6x
EV / EBITDA
-3.4x
Revenue
$0.00
ROCE
-47.7%

-64.6% over the last year

Perspective Therapeutics, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-67.4%
3M
-76.6%
6M
-80.1%
1Y
-64.6%
5Y
Hidden
  • This period includes a one-day price step on 21 Nov 2024 that looks like a share split or a similar corporate action. The figure is hidden until the price history is adjusted for it.

52-week range

Day change -$0.03 (-3.8%) from $0.78 to $0.75 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in CATX, bought on each weekday since 2021.

News & filings

What Perspective Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 103 million US dollars in fiscal 2025.

Strengths (1)

  • The company carries almost no debt: debt to equity of 0.02.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States.

Read moreShow less

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington.

Sector
Healthcare
Shares outstanding
74.3M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$370.7M
P/E
-3.6x
P/B
1.8x
EV / EBITDA
-3.4x
52-week high
$5.65
52-week low
$0.75

Profitability

ROE
-49.8%
ROCE
-47.7%
ROIC
-45.8%
ROA
-38.6%

Growth

Revenue
$0.00
Net profit growth, 1Y
30.1%
Free cash flow
-$95.2M

Solvency

Current ratio
5.17
Debt / Equity
0.02
Debt / Assets
0.01
CFO / Net profit
0.80
Cash / Market cap
8.3%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Perspective Therapeutics, Inc. revenue and net profit by fiscal year
Perspective Therapeutics, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$10.8M-$7.3M
FY2023$0.00-$46.5M
FY2024$0.00-$79.3M
FY2025$0.00-$103.1M

Cash flows

FY2025: -$82.5M from operations, -$95.2M free after investment (dashed).

Perspective Therapeutics, Inc. operating and free cash flow by fiscal year
Perspective Therapeutics, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$7.7M-$8.0M
FY2023-$36.9M-$38.0M
FY2024-$18.3M-$72.7M
FY2025-$82.5M-$95.2M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$100.8M
Net profit
-$103.1M
Cash from operations
-$82.5M
Free cash flow
-$95.2M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$100.8M-$103.1M-$95.2M-49.8%—+30.1%

Monthly returns

Month-by-month returns of CATX across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$267.0M
Liabilities$59.9M
Equity$207.0M
Paid-in capital$541.7M
Retained earnings-$334.8M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; CATX highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Perspective Therapeutics, Inc., Compass Therapeutics, Inc., Benitec Biopharma Inc., Lexeo Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Perspective Therapeutics, Inc.CATXthis company$370.7M-3.6x1.8x-49.8%-3.4x
Compass Therapeutics, Inc.CMPX$383.6M-5.8x1.9x-33.8%-5.1x
Benitec Biopharma Inc.BNTC$379.6M-10.0x3.9x-39.0%-6.8x
Viemed Healthcare, Inc.VMD$377.2M25.3x2.7x10.6%7.4x
CapsoVision, Inc.CV$376.7M-14.9x28.4x-190.9%-14.7x
Vanda Pharmaceuticals Inc.VNDA$375.8M—1.1x-67.4%—
Lexeo Therapeutics, Inc.LXEO$375.3M-3.8x1.5x-40.5%-3.3x
Delcath Systems, Inc.DCTH$372.5M138.0x3.3x2.4%327.0x
Puma Biotechnology, Inc.PBYI$356.8M11.5x2.7x23.9%6.7x
Peer median—-3.8x2.7x-36.4%-3.3x

Year-to-date ROI

CATX since 1 January, against earlier years.

Historical volatility

CATX's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Perspective Therapeutics, Inc. operating margin by fiscal year
Perspective Therapeutics, Inc. operating margin by fiscal year
DateOperating margin
FY2022-68.4%
FY2023—
FY2024—
FY2025—
LineFY2025
Cost of revenueCost Of Revenue—
Gross profitGross Profit—
Operating expensesOperating Expense$113.6M
Research and developmentResearch And Development$84.2M
Other operating expensesOther Operating Expenses-$880.0k
Total expensesTotal Expenses$113.6M
Pretax incomePretax Income-$104.4M

Learn while you research

Academy chapters picked for Perspective Therapeutics, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →